传闻已久的资生堂医美品牌终于"揭开面纱"！ 2 0 2 5 年 4 月 2 2 日 ， 资 生 堂 中 国 官 宣 旗 下 全 新 医 美 专 研 品 牌 「 律 曜 RQ PYOLOGY 」 （ 以 下 简 称：「律曜」）于上海首发。这是资生堂集团1 5 3年发展史上首个"专为亚洲肌打造"的高端术 研科技美肤品牌，最大的亮点是 以"械妆连用"的产品组合提供医美全周期的护理方案 ，集结 众多独家科技以实现"全面之美"。 对于新品牌的上市，资生堂中国及旅游零售CEO梅津利信表示：" 作为百年东方美先行者，资 生堂中国坚持'双管齐下'的创新战略，引入集团创新的同时，不断加码本土科研投资，把握新 兴的市场机遇。此次发布的律曜品牌将聚焦高端专业医美机构，通过高功效的械妆产品以及优 质的服务体验，为亚洲肌肤提供更安全、高效、精准的全周期美肤解决方案。 " 表面看，「律曜」的上市，意味着资生堂医美战略在中国迎来里程碑式的进展，这家百年老店 有望抓住大热的医美场景机遇迎来一波业务增长。但《FBe a u t y未来迹》研究发现，这一品牌 不仅在研发底层逻辑上有着超前的洞察和系统的解法，更是资生堂集团"成为个人美肤健康公 司 ...

Core Viewpoint - 九州通's subsidiary, Hubei Jiuzhou Industrial Park Operation Management Co., Ltd., signed a restructuring investment agreement with Aoyuan Meigu Technology Co., Ltd., planning to invest 673 million yuan to acquire 360 million shares post-restructuring [2][3] Group 1: Investment Details - The investment aims to make 九州通 the controlling shareholder of ST Meigu if the restructuring plan is successfully completed [3] - The restructuring investment is expected to positively impact 九州通's medical beauty business and align with its long-term strategic development plan [3] Group 2: Business Synergy - Aoyuan Meigu's medical beauty services have good synergy with 九州通's existing medical beauty operations, which have rapidly grown and now cover over 10,000 medical beauty service institutions nationwide [3] - 九州通 plans to leverage its strong pharmaceutical supply chain, efficient operational management, and advanced digital capabilities to enhance collaboration with Aoyuan Meigu in the beauty and health sector [3] Group 3: Implementation and Uncertainty - The specific implementation of the restructuring investment will depend on the court's approval of Aoyuan Meigu's restructuring plan [3] - There is uncertainty regarding the subsequent progress and effects of 九州通's participation in the restructuring investment, with no significant short-term impact on the company's operating performance [3]

Group 1 - The core point of the news is that Jiuzhoutong plans to invest 673 million yuan to acquire 360 million shares of Aoyuan Meigu, which is undergoing restructuring, indicating a strategic move into the beauty and health sector [1][2] - The investment is expected to positively impact Jiuzhoutong's medical beauty business and aligns with the company's long-term strategic development plan, enhancing its core competitiveness [2] - The collaboration between Jiuzhoutong and Aoyuan Meigu is anticipated to leverage Jiuzhoutong's strong pharmaceutical supply chain, operational management experience, and digital capabilities to expand the beauty and health industry [2][3] Group 2 - Jiuzhoutong's stock price is reported at 4.89 yuan per share, with a market capitalization of 24.658 billion yuan as of April 23 [2] - The investment is viewed positively by the market, as it aligns with the trend of the health industry, although there are uncertainties regarding Aoyuan Meigu's restructuring and potential challenges in business integration [3]

Core Viewpoint - In 2024, Sihuan Pharmaceutical continued to incur losses, with a net profit loss of 217 million yuan, a year-on-year increase of 301.1%, despite a slight revenue increase of 2.2% to 1.901 billion yuan. The company's performance is primarily affected by its generic drug business and innovation drug losses, while its medical aesthetics division shows growth but remains insufficient to reverse the overall decline [1][2]. Revenue and Profit Analysis - Sihuan Pharmaceutical's revenue for 2024 was 1.901 billion yuan, a 2.2% increase year-on-year, while the net profit loss was 217 million yuan, marking a 301.1% increase in losses compared to the previous year [2]. - The company has reported losses for three consecutive years, with net profit losses of 1.915 billion yuan in 2022, 54 million yuan in 2023, and 217 million yuan in 2024 [2]. - The revenue breakdown for 2024 shows that the generic drug segment generated 1.099 billion yuan, a decline of 21.4% and accounting for 58% of total revenue. The medical aesthetics segment achieved 744 million yuan, a growth of 65.4%, making up 39% of total revenue. The innovation drug segment generated 58 million yuan, up 388.1%, but only accounted for 3% of total revenue [2]. Business Segment Performance - The generic drug business, once a cash cow, has been negatively impacted by the inclusion of several products in the national monitoring directory, leading to a significant decline in average prices and sales volume [2]. - The medical aesthetics division has seen growth, but its contribution to overall performance is limited due to its smaller size [1][2]. - The innovation drug segment continues to incur substantial losses, with a reported loss of approximately 948 million yuan in 2024, despite ongoing research and development efforts [3][8]. R&D and Market Position - Sihuan Pharmaceutical is transitioning from generic drugs to innovative and biological drugs, maintaining high R&D spending despite slow commercialization progress [3]. - The company has significantly reduced its R&D personnel, with a decrease from 338 employees in September 2022 to 119 by June 2024, which raises concerns about the impact on future R&D projects [8][9]. - The approval of the "girl needle" product, a type of facial filler, may provide some support to the company's aesthetics business, but its overall impact on profitability remains uncertain [11]

□ 医美机构正遭遇业绩"卡壳"，平均客单价从2021年的6800元降至2023年的4200元，高值产品只能短暂 支撑收入，利润空间被压缩。 □ 医美机构经营能力面临迭代，要做好精细化经营。从投入产出最大化、人力产出最大化出发，做好客 户分级、品类精选、员工培训、服务标准化等工作，以效率制胜。 谈及医疗美容行业，不少人觉得一些项目动辄几千元甚至上万元，利润一定很高。但在日前召开的第八 届全球医学美容创新大会暨首届中国医美科普大会上，"利润持续走低"却成为高频词。 这一判断在几家医美上市公司财报中得到印证：瑞丽医美2024年亏损5921万元，公司归母净利润已连续 4年亏损；新三板华韩股份旗下有30家医美机构，华韩股份称，2024年预计净利润同比下降62%至 74%；ST美谷通过重大资产重组剥离房地产业务，开始了"中游切入，上游立足，下游卡位"的医美生态 集成商的场景化业务布局，2024年度，该公司归属于上市公司股东的净利润亏损3.2亿元至4.5亿元。 某连锁医美机构负责人表示，虽然客流量保持增长，但平均客单价从2021年的6800元降至2023年的4200 元，高值产品只能短暂支撑收入，利润空间被压缩。医美机构正 ...

艾尔建美学中国总经理丘汉华表示，中国是该公司的全球第二大市场，艾尔建美学始终将中国市场视为 全球业务的重要增长引擎，未来一方面会加快引入海外产品到中国上市，一方面也会通过与本土企业合 作，加快本土化发展。 作为大健康产业排头兵，外高桥保税区已推动多项创新成果落地，并加速建设国际医疗器械智造基地、 细胞和基因治疗跨境研发生产先行区，为区内企业提供从研发创新、临床转化到注册上市、流通入院等 全链条全环节的专业配套服务。 上海自贸试验区管委会保税区管理局副局长赵宇刚表示，目前，保税区域内已集聚800余家生物医药产 业链企业，成为上海打造世界级生物医药产业集群的重要支撑。 诸耀鹏进一步表示，外高桥保税区在保税分拨、进口贴标、产业政策配套、供应链管理服务、出海等方 面都具有显著的政策及服务优势，因此成为众多跨国公司中国区总部的所在地。对于医美产业来说，上 游的原材料供应商可以利用保税区域的通关便利化和保税政策，降低生产的成本，并确保原材料的质量 和供应的及时性。同时，可以依托外高桥出海桥头堡的优势，加大海外市场的拓展。对于医美下游企 业，外高桥也将考虑帮助医美机构、经销商与同龙头医美企业建立合作关系，推动新产品在中国的 ...

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - The report highlights the growth potential in the medical beauty and cosmetics sectors, driven by innovative products and changing consumer preferences towards self-care and emotional consumption [6][7][36][50] - The medical beauty segment is expected to benefit from the approval of new products, particularly in the recombinant collagen market, which is gaining traction as a substitute for animal-derived collagen [6][31][49] - The cosmetics industry is witnessing a rise in domestic brands, with a focus on high-quality products and emotional connections with consumers, suggesting a shift towards "self-care" trends [7][36][50] Summary by Sections Market Review - The beauty and personal care index rose by 3.41% in March, outperforming the broader market [15][18] - Notable stock performances in the medical beauty sector included Jinbo Biological (+32.2%), Furuier Medical Technology (+22.8%), and Kedi-B (+9.5%) [19] - In the cosmetics sector, Shangmei Co. (+31.8%), Maogeping (+31.6%), and Runben Co. (+16.4%) led the gains [25] Medical Beauty - Jinbo Biological received approval for its recombinant type III human collagen gel, marking a significant advancement in the medical beauty field [6][31] - The product offers dual benefits of filling and repairing, positioning Jinbo as a leader in the recombinant collagen market [31][33] - The report emphasizes the importance of differentiated strategies in the recombinant collagen industry, including technological advancements and diverse product offerings [33] Cosmetics - The report identifies the "self-care" trend as a key driver in the cosmetics market, with consumers increasingly seeking products that enhance their emotional well-being [7][36] - It suggests focusing on domestic brands that are adapting to market trends and consumer preferences, particularly in high-growth segments [37][50] - The report highlights the rise of high-end domestic brands, with Maogeping being a notable example, leveraging its unique brand identity and product quality [42][50] Investment Recommendations - The report recommends focusing on leading domestic beauty brands that are expected to gain market share, including Maogeping, Shangmei Co., and Runben Co. [49][50][53] - It suggests that the medical beauty sector will see growth driven by new product launches and the increasing acceptance of domestic brands [49][51] - The report anticipates that the emotional consumption trend will continue to shape the cosmetics market, creating opportunities for brands that can connect with consumers on a deeper level [50][51]

Core Viewpoint - The company is undergoing a significant business transformation, shifting focus from an online medical beauty platform to a chain of physical clinics, while also extending upstream in the industry chain [2][3]. Financial Performance - In 2024, the company's total revenue is projected to be 1.47 billion yuan, a year-on-year decrease of 2.1%, with core business revenue from information and appointment services dropping 19.3% to 930 million yuan [2]. - The chain business, however, has shown remarkable growth, achieving revenue of 170 million yuan, a year-on-year increase of over 1200% [2]. Business Strategy - The CEO indicated that the transformation was necessary due to the increasing competition from larger platforms like Meituan and Alibaba, which have a competitive edge in online traffic [2]. - The company aims to establish itself as the largest offline brand in the domestic medical beauty industry, with plans to expand from 25 to 50 clinics by the end of the year and ultimately to 1000 clinics in the long term [3]. Market Positioning - The new clinics, named "Xinyang Youth Clinics," focus on "light medical beauty" services, offering high-quality, low-cost treatments without the need for surgical procedures [8][10]. - The clinics operate on a model that avoids traditional practices like membership cards and prepayments, aiming to maximize profit margins through self-operated services [10]. Competitive Landscape - The company faces challenges from existing medical beauty institutions, which view its entry into the physical clinic space as a threat to their business [5][6]. - Despite some backlash, many institutions have chosen to continue their partnerships with the company, indicating a recognition of the potential for market expansion [6]. Future Outlook - The company has invested significantly in upstream operations, including acquiring stakes in medical device companies and establishing its own production facilities for beauty products [8][9]. - The CEO believes that the medical beauty market in China is still growing, with the potential for the company to capture a larger market share despite current financial pressures [12][14].

Core Insights - The medical aesthetics industry has become a significant component of the Shanghai Waigaoqiao Free Trade Zone, attracting multinational companies' regional headquarters [1][2] - Shanghai's biopharmaceutical industry is one of the three leading industries in the city's goal to create a world-class industrial cluster [1] - The Waigaoqiao Free Trade Zone has developed into the largest economic scale and most functionally diverse customs special supervision area in China [1] Industry Overview - The global medical aesthetics market is currently valued at approximately $23 billion, with an expected annual growth rate of around 7% over the next five years [2] - The Chinese medical aesthetics market is projected to reach ¥270 billion in 2024, reflecting a year-on-year growth of about 10% [2] Company Developments - Over 800 biopharmaceutical companies have gathered in the Waigaoqiao Free Trade Zone, supporting Shanghai's ambition to build a world-class biopharmaceutical industry cluster [1] - The Waigaoqiao Free Trade Zone offers significant policy and service advantages, making it an attractive location for multinational companies' China headquarters [2] - Allergan Aesthetics established its third wholly-owned subsidiary in China six years ago, marking a significant step in its development in the Chinese market [2]

Core Insights - The company reported a total revenue of approximately 41.91 billion yuan in 2024, representing a year-on-year increase of 3.16% compared to 40.62 billion yuan in 2023 [1] - The pharmaceutical industry is experiencing significant growth driven by the introduction of new products into the medical insurance catalog, with notable sales increases in innovative drugs and biosimilars [3] - The company has established a strong market presence in specialized chronic disease treatment areas, maintaining a leading market share in various therapeutic fields [3] Revenue Breakdown - Total revenue for 2024 was 41.91 billion yuan, with the commercial sector contributing 28.47 billion yuan (67.94% of total revenue), and the manufacturing sector contributing 15.78 billion yuan (37.65% of total revenue) [1] - The medical beauty business generated 2.33 billion yuan, showing a decline of 4.94% from the previous year [1][8] - Internal sales accounted for 97.39% of total revenue, while external sales made up 2.61%, with external sales decreasing by 23.29% year-on-year [1] Product and Market Development - The company has a comprehensive pipeline of over 20 products in the diabetes treatment sector, covering various clinical mainstream targets [4] - In the field of autoimmune diseases, the company has over 20 products in development, with a focus on a wide range of conditions [4] - The medical beauty segment is expected to stabilize and grow, with the company actively expanding its global market presence through subsidiaries [8] Financial Performance - The core subsidiary, China Medical East, achieved sales revenue of 13.81 billion yuan, a year-on-year increase of 13.05%, and a net profit of 2.88 billion yuan, up 29.04% [5] - The pharmaceutical commercial segment reported revenue of 27.09 billion yuan, a slight increase of 0.41%, with a net profit of 456 million yuan, up 5.58% [7] - The industrial microbiology segment saw a significant revenue increase of 43.12%, with various sub-segments experiencing substantial growth [8]